PubMed ID:
33010412
Public Release Type:
Journal
Publication Year: 2020
Affiliation: Division of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, California. Electronic address: monika.sarkar@ucsf.edu.; Division of Gastroenterology and Hepatology, Duke University, Durham, North Carolina.; Division of Gastroenterology and Hepatology, Duke University, Durham, North Carolina.; Department of Epidemiology and Biostatistics, Johns Hopkins University, Baltimore, Maryland.; Department of Epidemiology and Biostatistics, Johns Hopkins University, Baltimore, Maryland.; Division of Gastroenterology and Hepatology, University of California, San Francisco, San Francisco, California.; Department of Pathology, University of California, San Francisco, San Francisco, California.; Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of California, San Francisco, San Francisco, California.; Division of Gastroenterology and Hepatology, University of Southern California, Los Angeles, California.
DOI:
https://doi.org/10.1016/j.cgh.2020.09.045
Authors:
Sarkar Monika, Suzuki Ayako, Abdelmalek Manal, Yates Katherine, Wilson Laura, Bass Nathan M, Gill Ryan, Cedars Marcelle, Terrault Norah
Request IDs:
21167
,
21177
,
21318
,
21513
,
21515
,
21668
,
21721
,
22585
,
22613
Studies:
The Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment
Higher testosterone contributes to imaging-confirmed nonalcoholic fatty liver disease (NAFLD) in women, but whether testosterone influences their disease severity is unknown.